SYSTEMATIC REVIEW AND META-ANALYSIS

Meta-Analysis of Intensive Lipid-Lowering Therapy in Patients With Polyvascular Disease

Mohammad Alkhalil, MRCP, DPhil; Michał Kuzemczak, MD, PhD; Nicholas Whitehead, BMed; Charalampos Kavvouras, MD, MSc; Vladimír Džavík, MD

BACKGROUND: Polyvascular atherosclerotic disease is associated with an increased risk of future cardiovascular events. Intensive lipid-lowering therapy (ILT) may mitigate this risk. The aims of this study-level meta-analysis were to examine the effects of ILT in patients with polyvascular disease and whether baseline low-density lipoprotein cholesterol (LDL-C) may determine the level of benefit.

METHODS AND RESULTS: Electronic databases were searched through January 2020 to identify randomized controlled trials of treatments targeting upregulation of LDL-C receptors (ie, statins, ezetimibe, and PCSK9 [proprotein convertase subtilisin–kexin type 9] inhibitors). The primary end point was major adverse vascular events as defined by the included studies. A total of 94,362 patients (14,821 [18.6%] with polyvascular disease) from 7 studies were included. In patients with monovascular disease, ILT was associated with a 13% reduction in the primary end point (rate ratio [RR] 0.87; 95% CI, 0.81–0.93 [P=0.0002]) (absolute RR, 1.8%) compared with less ILT, while patients with polyvascular disease had 15% relative RR (0.85; 95% CI, 0.80–0.90 [P<0.00001]) (absolute RR, 6.5%) (P=0.66 for interaction). When factoring LDL-C, unlike patients with monovascular disease, the relative benefits of ILT, compared with less ILT, in patients with polyvascular disease were comparable with LDL-C >100 mg/dL (RR, 0.85; 95% CI, 0.80–0.90 [P<0.00001]) and LDL-C <100 mg/dL (RR, 0.88; 95% CI, 0.81–0.96 [P=0.003]) (P=0.23 for interaction).

CONCLUSIONS: Patients with polyvascular disease experienced comparable benefits to those with monovascular disease in response to ILT. The benefits of ILT in patients with polyvascular disease were not dependent on baseline LDL-C, challenging the approach of using LDL-C as a prerequisite to commence ILT for this high-risk subgroup.

Key Words: lipid-lowering ■ low-density lipoprotein cholesterol ■ polyvascular

Polyvascular disease, defined as the presence of atherosclerosis in at least 2 vascular beds, is a well-established high-risk feature for adverse cardiovascular events.1 The REACH (Reduction of Atherothrombosis for Continued Health) registry demonstrated that 1 in 6 patients with stable atherosclerosis disease had clinical evidence of atherosclerosis in a second or more vascular territories.2 The CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) registry showed the close association between ischemic events, including mortality, and the number of affected vascular beds.1

The heightened risk associated with polyvascular disease has been a target using different pharmacological modalities.3 Lipid-lowering therapies modify the risk in patients with atherosclerosis and have been shown to exert larger absolute risk reductions in patients with polyvascular disease.4,5 Moreover, the advent of PCSK9 (proprotein convertase subtilisin–kexin type 9) inhibitors has also allowed to further

Correspondence to: Vladimír Džavík, MD, FRCPC, and Mohammad Alkhalil, MRCP, DPhil, Peter Munk Cardiac Centre, University Health Network, 6-246A EN, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4. E-mail: vlad.dzavik@uhn.ca; mak-83@hotmail.com
For Sources of Funding and Disclosures, see page 9.
© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
J AHA is available at: www.ahajournals.org/journal/jaha

J Am Heart Assoc. 2021;10:e017948. DOI: 10.1161/JAHA.120.017948

1
mitigate the lipoprotein-related risk associated with polyvascular disease.\textsuperscript{5,7} The initial Task Force of European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) recommended the addition of PCSK9 inhibitors in patients with severe polyvascular disease to reach the goal of low-density lipoprotein cholesterol (LDL-C) of <100 mg/dL.\textsuperscript{8} This was recently updated and the current European guidelines recommend that the lower the LDL-C level the better.\textsuperscript{9} Nonetheless, a large meta-analysis reported benefit from intensive lipid-lowering therapy (ILT) only in patients with LDL-C >100 mg/dL, with a lack of association of benefit in patients with baseline LDL-C <100 mg/dL.\textsuperscript{10} Importantly, polyvascular disease was not considered in the meta-analysis.\textsuperscript{10}

Therefore, the aim of this study-level meta-analysis was to determine whether intensive LDL-C reduction was associated with larger risk reduction in patients with polyvascular disease compared with monovascular disease. In addition, we sought to assess whether there was any heterogeneity between monovascular and polyvascular disease in the relative benefits of intensive lipid lowering according to baseline LDL-C.

\textbf{CLINICAL PERSPECTIVE}

\textbf{What Is New?}
- Intensive lipid-lowering therapy did not result in a consistent relative risk reduction in polyvascular disease despite their heightened cardiovascular risk.
- The current meta-analysis demonstrated that larger intensive lipid-lowering therapy resulted in larger absolute benefits in patients with polyvascular disease.

\textbf{What Are the Clinical Implications?}
- Patients with polyvascular disease have comparable benefits from intensive lipid-lowering therapy irrespective of their low-density lipoprotein cholesterol.

\textbf{METHODS}

The data that support the findings of this study are available from the corresponding authors on reasonable request. The MEDLINE and the Cochrane Central Register of Controlled Trials databases were searched from inception until January 2020 using the following keywords: lipid-lowering, hypercholesterolemia, low-density lipoprotein, cholesterol, randomized controlled trial, and polyvascular disease.

Studies were included if they were randomized trials that compared lipid-lowering therapies and where major cardiovascular events was the primary end point. Lipid-lowering therapies were included if their primary mechanism was targeting LDL-C via the up-regulation of low-density lipoprotein receptor expression such as statins, ezetimibe, or PCSK9 inhibitors.\textsuperscript{11} Data on the effects of bempedoic acid in polyvascular disease have not been reported. Studies of fibrates, niacin, and cholestereryl ester transfer protein inhibitors were excluded since these pharmacotherapies do not directly target the upregulation of low-density lipoprotein receptor expression. Additionally, studies investigating the efficacy of lipid-lowering therapy in specific cohorts, such as heart failure or end-stage renal disease, were also excluded.

All included articles had initial assessment using the prespecified inclusion criteria by 2 authors (M.A. and M.K.), neither of whom was an investigator in any of the selected studies. Any cases of disagreement were resolved by consensus. Citations were

\textbf{Nonstandard Abbreviations and Acronyms}
screened at title/abstract level and full reports were retrieved when considered relevant. The search results were cross-checked by reviewing systematic reviews and meta-analyses on lipid-lowering treatments. A study was included if a specific subgroup analysis investigating patients with polyvascular disease was reported. Similarly, the literature was searched to identify dedicated studies targeting the role of lipid-lowering therapy in patients with polyvascular disease. The identified records were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.12,13

Control groups from the original trials were assigned as the less intensive lipid-lowering strategy, while the more intensive therapy was defined as the experimental group or the more intensive lipid-lowering strategy of the original studies as previously described.10 Therefore, the intensity of statin treatment was not assessed in absolute terms but rather relative to the comparable group. Since simvastatin (40 mg) and pravastatin (40 mg) were compared with placebo in HPS (Heart Protection Study) and WOSCOP (West of Scotland Coronary Prevention Study), respectively, the statin arms were included in the intensive lipid-lowering group.14,15

Major adverse cardiovascular events were defined according to the reported events within the selected studies. Data on mortality according to the status of polyvascular disease were not specifically reported in the majority of the studies and, therefore, exploring their association could not be reliably executed in our analysis.

Statistical Analysis

Continuous data are presented as mean±SD or as median (range), while categorical variables are presented as percentages, as reported in the original studies.

Using trial-level data, treatment effect was reported as rate ratio (RR) with 95% CIs adjusted by patient-years, which was used as a unit alongside the total number of events to calculate the RR of ILT versus less ILT to account for the potential differences in study duration. Subsequently, a summary RR was calculated with the random-effects models based on the inverse variance method. We elected to use random effect to relatively weight the studies equally since all included studies were large randomized trials. The presence of heterogeneity among studies was assessed using the Cochran Q (or chi-square) test and quantified using the Higgins I² test.12

Sensitivity analysis was performed to identify any heterogeneity in the treatment effect of lipid-lowering therapy among the studies. A cutoff value for baseline LDL-C of 100 mg/dL was used to perform the sensitivity analysis.13 Publication bias was evaluated using funnel plot methodology. The statistical analysis was performed using RevMan software version 5.3 (Cochrane Collaboration) and P<0.05 were considered statistically significant.

RESULTS

Using our search strategy, we initially identified 3441 records. The PRISMA flow diagram of the selected studies is shown in Figure 1. Seven randomized studies met the inclusion criteria, totaling 94 362 patients, of whom 47 538 (50.4%) were in the more intensive lipid-lowering group. This included high-dose statins and PCSK9 inhibitors in 2 trials,6,7 high-dose statin and ezetimibe in 1 study,5 high-dose statin in 3 trials,4,14,16 and moderate-dose statin in 1 study.15 Six studies were excluded as ILT could not be established given the comparable or undetermined intensity of the studied lipid-lowering regimens.17–22 Similarly, studies investigating the role of early administration of lipid-lowering therapy on clinical outcomes were excluded as time-based analyses.23–25

WOSCOP is considered a primary prevention study; nonetheless, data on clinical outcomes in patients with multiple risk factors including angina and claudication were reported. Therefore, this study was included in the final analysis.

The total number of patients with polyvascular disease was 14 821 (18.6%). The baseline clinical characteristics of each study are reported in the Table. The baseline LDL-C value was <100 mg/dL in 4 studies. Patients with stable disease were included in 4 studies.

Risk of publication bias was assessed by visual inspection of the funnel plots for both monovascular and polyvascular disease (Figure 2). While there was no bias in reported data on polyvascular disease, studies of monovascular disease had moderate between-trial heterogeneity (I²=74%, P=0.0009).12 Nonetheless, all included studies were randomized, blinded, and multicenter; and the reported data were according to the intention-to-treat analysis.

In patients with monovascular disease, the number of events in patients receiving ILT was 5919 (15%), compared with 6775 (16.9%) for those receiving less ILT. The difference between the 2 strategies was associated with a 13% reduction in major cardiovascular events (RR, 0.87; 95% CI, 0.81–0.93 [P=0.0002]) (Figure 3). The absolute risk reduction of ILT compared with less ILT was 1.8% (95% CI, 1.3–2.3), which was translated into a number needed to treat (NNT) of 55 (95% CI, 43–76).

On the other hand, there were 2010 (24.5%) major vascular events in patients with polyvascular disease.
receiving ILT compared with 2060 (31.1%) major vascular events in patients with polyvascular disease receiving less ILT. This translated into a 15% reduction in major vascular events (RR, 0.85; 95% CI, 0.80–0.90 [P<0.00001]) (Figure 3). The absolute risk reduction of ILT versus less ILT was 6.5% (95% CI, 5.0–7.9), reflecting an NNT of 15 (95% CI, 12–19).

There was no significant heterogeneity in the relative benefits of more versus less ILT according to the number of vascular beds with atherosclerotic disease (P=0.66 for subgroup differences). The lack of interaction remained evident even after excluding studies using placebo as a comparator group (P=0.35 for subgroup differences).

Role of LDL-C

When the studies were stratified according to a cutoff LDL-C value of 100 mg/dL, patients with monovascular disease with an LDL-C level >100 mg/dL who were subjected to more versus less ILT had a 21% reduction in major vascular events (RR, 0.79; 95% CI, 0.68–0.92 [P=0.03]) compared with a 9% risk reduction in those with an LDL-C level <100 mg/dL (RR, 0.91; 95% CI, 0.87–0.96 [P=0.001]) (Figure 4). The difference in treatment effect did not reach statistical significance (P=0.08). The absolute risk reduction between ILT and less ILT was 3.2% (95% CI, 2.3–4.1) and 1.2% (95% CI, 0.6–1.8) in patients with LDL-C >100 mg/dL and <100 mg/dL, with corresponding NNT of 31 (95% CI, 24–43) and 81 (95% CI, 54–161), respectively.

In contrast, the relative benefits of ILT versus less ILT were consistent between patients with polyvascular disease with LDL-C >100 mg/dL (RR, 0.85; 95% CI, 0.80–0.90 [P<0.00001]) and those with LDL-C <100 mg/dL (RR, 0.88; 95% CI, 0.81–0.96 [P=0.003]) (P=0.23 for interaction) (Figure 4). The absolute risk reduction of ILT compared with less ILT was higher in patients with polyvascular disease but comparable across the strata of LDL-C, 5.7% (95% CI, 3.6–7.8) in patients with polyvascular disease who had LDL-C >100 mg/dL and 7.2% (95% CI 5.2–9.2) in those with LDL-C <100 mg/dL. The NNT was 17.5 (95% CI, 12–27) and 14 (95% CI, 10–19), respectively. When patients with polyvascular disease were stratified according to their clinical presentation, the relative benefits of ILT was consistent in stable patients (RR, 0.83; 95% CI, 0.80–0.90 [P<0.0001]) and those with recent myocardial infarction (RR, 0.89; 95% CI, 0.79–1.00 [P=0.04]) (P=0.34 for interaction).
| Study | ODYSSEY OUTCOMES | FOURIER | IMPROVE-IT | IDEAL | SEARCH | HPS | WOSCOP |
|-------|-----------------|---------|------------|-------|--------|-----|--------|
| No.   | 18,924          | 27,564  | 18,144     | 8888  | 12,064 | 20,536 | 6,595  |
| Monovascular | 17,370          | 19,113* | 16,204     | 8514  | 5,845* | 9395* | 5,401  |
| Polyvascular | 1,554           | 3,563   | 1,930      | 374   | 1,062  | 5,507 | 1,194  |
| Studied lipid-lowering therapy | Alirocumab compared with placebo in patients receiving statin | Evolocumab compared with placebo in patients receiving statin | Ezetimibe and simvastatin compared with simvastatin (40 mg) | Atorvastatin (80 mg) compared with simvastatin (20 mg) | Simvastatin (80 mg) compared with simvastatin (20 mg) | Simvastatin (40 mg) compared with placebo | Pravastatin (40 mg) compared with placebo |
| Age, y | 59±9            | 63±9    | 64±10      | 62±10 | 64±9   | ...   | 55±6   |
| Women, n (%) | 4762 (25)       | 6769 (25) | 4416 (24) | 1701 (19) | 2052 (17) | 5,082 (25) | ...   |
| MI, n (%) | 3633 (19)       | 22,351 (81) | 3806 (21) | 1494 (17) | 12,064 (100) | 8,510 (41) | 338† (5) |
| CVD, n (%) | 611 (3)         | 5,337 (19) | 1,071 (6) | 729 (8) | 837 (7) | 3,280 (16) | ...   |
| PVD, n (%) | 759 (4)         | 3,642 (13) | 1,006 (6) | 377 (4) | ...    | 6,748 (33) | 193 (3) |
| Diabetes mellitus, n (%) | 5,444 (29)     | 10,081 (37) | 4,933 (27) | 10,69 (12) | 1,267 (11) | 5,963 (29) | 76 (1) |
| LDL-C | 92±31           | 92 (61–108) | 94        | 122   | 97±24  | 1,31±31 | 192±17 |
| Clinical presentation | ACS             | Stable   | ACS        | ACS   | Stable | Stable | Stable |
| Major vascular events | CHD, MI, ischemic stroke, or unstable angina requiring hospitalization | CVD, MI, stroke, hospitalization for unstable angina, or coronary revascularization | CVD, MI, unstable angina requiring rehospitalization, or coronary revascularization | CHD, MI, or cardiac arrest with resuscitation | CHD, MI, stroke, or arterial revascularization | CHD, MI, strokes of any type, and coronary, or noncoronary revascularizations | CHD or MI |

ACS indicates acute coronary syndrome; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; HPS, Heart Protection Study; IDEAL, Incremental Decrease in End Points Through Aggressive Lipid Lowering; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; LDL-C, low-density lipoprotein cholesterol; ODYSSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; PVD, peripheral vascular disease; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; and WOSCOP, West of Scotland Coronary Prevention Study.

*Only patients with previous myocardial infarction were included; stroke, peripheral artery disease, or diabetes mellitus alone were not used in the analysis.

†History of angina, coronary heart death (CHD), cardiovascular death (CVD), or myocardial infarction (MI).
DISCUSSION

This is the first meta-analysis to investigate the role of ILT in patients with polyvascular disease. The main findings of this meta-analysis can be summarized as follows: (1) polyvascular disease is common, with almost 1 in 5 patients having atherosclerotic disease involving at least 2 vascular beds; (2) the relative benefit of ILT is evident in both patients with monovascular disease and those with polyvascular disease, although the absolute benefit is larger in those with polyvascular disease; (3) patients with monovascular disease and LDL-C >100 mg/dL may sustain a greater benefit from ILT compared with individuals with LDL-C <100 mg/dL; and (4) patients with polyvascular disease have comparable benefits irrespective of their LDL-C, reflecting the heightened risk in this group.

Atherosclerosis is a systemic disease resulting from complex and intricate processes affecting the intima of the vascular wall. The contributing risk factors are similar across the world including hypertension, hypercholesteremia, and diabetes mellitus. The systemic nature of lipoprotein retention means that atherosclerotic plaques are not confined to a single vascular bed. The recognition of the heightened risk in patients with polyvascular disease have prompted few recent trials to study this subgroup specifically. Both the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) and the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) study reported higher risk in patients with polyvascular disease compared with those with monovascular disease. Nonetheless, the relative risk reduction of ILT was comparable in patients with monovascular and polyvascular disease. This is in line with the consistent decrease in major adverse events that was found to be associated with LDL-C reduction using statins among patients with different clinical characteristics. Our data show a similar relative risk reduction in patients with polyvascular disease when compared with individuals with monovascular disease. On the other hand, patients with polyvascular disease obtained a greater absolute risk reduction (6.5% versus 1.8%) and a lower NNT (15 versus 55) compared with those with monovascular disease. Notably, the absolute risk reduction was consistent in polyvascular disease, irrespective of baseline LDL-C. In contrast, the absolute risk reduction was almost 3 times larger in those with LDL-C >100 mg/dL compared with LDL-C <100 mg/dL (3.2% versus 1.2%, respectively) in patients with monovascular disease. It is widely recognized that patients with heightened baseline lipoprotein-related risk are likely to experience more benefits when treated with more intensive therapy.

Figure 2. Publication bias for major vascular events, stratified according to the number of atherosclerotic vascular beds. Funnel plots of included studies in the meta-analysis. The horizontal axis represents the rate ratio (RR), while the vertical axis reflects the standard error of log RR. The vertical and sloping dotted lines represent the pooled RR and expected 95% CIs for a given standard error (SE), respectively.
risk models, such as polyvascular disease, is of urgent need since these patients may benefit maximally from novel therapies such as PCSK9 inhibitors. Moreover, the milder regression of coronary atherosclerosis using statin in patients with polyvascular disease compared with monovascular disease provides a mechanistic indication to commence ILT, such as PCSK9 inhibitors, in this cohort.30 However, the benefits of ILT was not consistently borne out in previous studies of patients with polyvascular disease.5 The quantification of “polyvascular” disease as a potential substrate requires more robust evaluation. The mechanistic heterogeneity in atherosclerotic disease processes would render the use of the category of disease, such as cerebral or peripheral vascular disease, less precise in assessing future risk. Moreover, for new treatment to achieve any potential risk reduction, its therapeutic effects should target the disease processes that determine the nature of heightened risk. For lipoprotein-related risk, the benefits of LDL-C reduction are associated with a decrease in atherosclerosis burden and/or change in plaque composition.31–33 Indeed, when a category of disease reflects a large atherosclerotic burden, such as post-coronary artery bypass surgery, the relative benefits of ILT become more sizeable.11 The extended benefit of intensive lipid-lowering is even associated with a reduction in cardiovascular mortality.11

Advances in novel plaque imaging have enabled us to detect the multifocal process of atherosclerotic disease.32,34 The presence of atherosclerotic plaques, even in their pre-clinical stage, is associated with increased risk of future cardiovascular events.35,36 Importantly, the burden of these plaques is modifiable using lipid-lowering therapies.32 The use of novel imaging techniques could serve as a risk stratification tool to identify patients with propensity to develop atherosclerotic plaques at multivascular sites.37,38 This approach targets a specific process of the atherosclerotic disease, such as lipid accumulation, rather than merely a category of diagnosis and may identify those patients who may benefit maximally from ILTs.29

Our data are consistent with previous large meta-analyses highlighting that the greatest benefits of LDL-C-lowering therapy may occur for patients with baseline LDL-C >100 mg/dL.10 The current meta-analysis showed that LDL-C would serve as a
clinical discriminator in patients with monovascular disease in identifying individuals who may sustain larger benefits from intensive LDL-C reduction. On the other hand, in polyvascular disease, there is a lack of interaction between LDL-C and the magnitude of benefit of ILT. Importantly, previous studies have also demonstrated the magnitude of LDL-C reduction to be comparable irrespective of the number of diseased vascular beds.\(^6\) This challenges the use of LDL-C level as a single metric in decision-making regarding the use of intensive and novel therapies.\(^26\) While LDL-C may be less informative as a tool for risk stratification on an individual basis, this should not overlook its established role as a risk factor in large cohort studies. The use of novel plaque imaging would provide better characterization of individual patients and could be used as a stratification tool to identify high-risk patients. Moreover, direct quantification of the burden of atherosclerotic disease would allow the effects of standard therapies to be monitored serially and to identify patients with a lack of response as candidates for novel lipid-lowering therapies.\(^32\)

We used a cutoff LDL-C level of 100 mg/dL to determine whether baseline LDL-C is a useful marker to aid decision-making for ILT in patients with polyvascular disease. We recognized that this cutoff was higher than recommended LDL-C targets in the current guidelines and might reflect a potential source of bias. Nonetheless, the updated European Task force acknowledged that these LDL-C targets were not examined systematically in randomized clinical trials. Moreover, a large meta-analysis suggested a lack of clinical benefits with intensive LDL-C reduction in patients with baseline LDL-C <100 mg/dL. Finally, recent studies, including those conducted on a background of high-intensity statin therapy such as the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; HPS, Heart Protection Study; IDEAL, Incremental Decrease in End Points Through Aggressive Lipid Lowering; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; LL, lipid-lowering therapy; ODYSSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; and WOSCOP, West of Scotland Coronary Prevention Study.

### Figure 4.

Meta-analysis of major cardiovascular events stratified according to baseline low-density lipoprotein cholesterol (LDL-C).

Rate ratios and 95% CIs of more intensive vs less intensive lipid-lowering therapies in patients with monovascular disease and polyvascular disease, stratified according to baseline LDL-C >100 or <100 mg/dL. FOURIER indicates Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; HPS, Heart Protection Study; IDEAL, Incremental Decrease in End Points Through Aggressive Lipid Lowering; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; LL, lipid-lowering therapy; ODYSSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; and WOSCOP, West of Scotland Coronary Prevention Study.

| Monovascular disease | Polyvascular disease |
|----------------------|----------------------|
| Rate Ratio | Rate Ratio | Rate Ratio | Rate Ratio |
| Rate Ratio | Rate Ratio | Rate Ratio | Rate Ratio |
| Rate Ratio | Rate Ratio | Rate Ratio | Rate Ratio |
| Rate Ratio | Rate Ratio | Rate Ratio | Rate Ratio |
| Rate Ratio | Rate Ratio | Rate Ratio | Rate Ratio |

**Table 4.** Meta-analysis of major cardiovascular events stratified according to baseline low-density lipoprotein cholesterol (LDL-C).
all included studies. Additionally, there was evidence of heterogeneity in patients with monovascular disease and this is likely to reflect the difference in the included comparator group and the definition of the primary end point.

CONCLUSIONS

Patients with polyvascular disease experience comparable benefits to those with monovascular disease in response to ILT. While there are differential incremental benefits of ILT according to baseline LDL-C in patients with monovascular disease, patients with polyvascular disease show similar relative risk reduction irrespective of LDL-C. Considerations should be taken in using more potent therapies such as PCSK9 inhibitors to mitigate the elevated risk associated with polyvascular disease even if LDL-C is <100 mg/dL.

ARTICLE INFORMATION

Received June 30, 2020; accepted December 15, 2020.

Affiliations

From the Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada (M.A., M.K., N.W., C.K., V.D.); Department of Cardiothoracic Services, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom (M.A.); Division of Emergency Medicine, Poznan University of Medical Sciences, Poznań, Poland (M.K.); and Department of Interventional Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland (M.K.).

Sources of Funding

None.

Disclosures

None.

REFERENCES

1. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RD, Peacock WF, Brer CJ, et al. Prior polymor- 

vascular disease: risk factor for adverse ischaemic outcomes in acute cor-

onary syndromes. Eur Heart J. 2009;30:1195–1202.DOI: 10.1093/eurhe-

art/eph099.

2. Bhatt DL, Steg PG, Ohman EM, Hirsh AT, Ikekda Y, Mas JL, Goto S, Liao CS, Richard AJ, Rother J, et al. International prevalence, rec-

ognition, and treatment of cardiovascular risk factors in outpatients 

with atherothrombosis. JAMA. 2006;295:180–189.DOI: 10.1001/jama.

295.2.180.

3. Gutierrez JA, Adzy AW, Patel MR, Jones WS. Polyvascular disease: 

reappraisal of the current clinical landscape. Circ Cardiovasc Interven-

2019;12:e007385.DOI: 10.1161/CIRCU L ATIO N.HA.119.007385.

4. Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen 

M, Kuder J, Murphy SA, Jukema JW, Lewis BS, et al. Low-density lipopro-

tein cholesterol lowering with evolocumab and outcomes in patients 

with peripheral artery disease: insights from the FOURIER Trial (Fur-

ther Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects 

With Elevated Risk). Circulation. 2018;137:338–350.DOI: 10.1161/ CIRC-

ULATIONNAHA.117.032235.

5. Bonaca MP, Nault P, Giugliano R, Blazing M, et al. A re-appraisal of the current clinical landscape. Circ Cardiovasc Interv. 2013.12.003.

6. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, 

Diaz R, Edelberg JM, Goodman SG, Hanotin C, et al. Alirocumab in pa-

tients with polyvascular disease and recent acute coronary syndrome: 

ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;74:1167–1176.

7. Bonaca MP, Nault P, Giugliano R, Kuder J, Murphy SA, Jukema JW, Lewis BS, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137:338–350.DOI: 10.1161/CIRCULATIONNAHA.117.032235.

8. Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JF, Borén 

J, Farnier M, Ference BA, Gielen S, Graham I, et al. 2017 update of ESC/ 

EAS Task Force on practical clinical guidance for proprotein con-

vertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic 

cardiovascular disease or in familial hypercholesterolaemia. Eur Heart 

J. 2018;39:1131–1143.DOI: 10.1093/eurheartj/ehy549.

9. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, 

Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/ 

EAS guidelines for the management of dyslipidaemias: lipid modifica-

tion to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.DOI: 

10.1093/eurheartj/ehz545.

10. Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti 

F, Bleden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association be-

tween baseline LDL-C level and total and cardiovascular mortality 

after LDL-C lowering: a systematic review and meta-analysis. JAMA. 

2019;319:1566–1579.DOI: 10.1001/jama.2019.2525.

11. Alkhalil M. Effects of intensive lipid-lowering therapy on mortality 

after coronary bypass surgery: a meta-analysis of 7 randomised trials. 

Atherosclerosis. 2020;293:75–78.DOI: 10.1016/j.atherosclerosis.2019.12.006.

12. Higgins J, Thompson S. Cochrane handbook for systematic reviews of 

interventions version 5.1.0. Cochrane Collaboration. 2011.

13. Moher D, Liberati A, Tetzlaff J, Altman DG; Group P. Preferred re-

porting items for systematic reviews and meta-analyses: the PRISMA 

statement. J Clin Epidemiol. 2009;62:1006–1012.DOI: 10.1016/j.jclepi. 

2009.06.005.

14. Heart Protection Study Collaborative G, MRC/BHF Heart Protection 

Study of cholesterol lowering with simvastatin in 20,536 high-risk indi-

viduals: a randomised placebo-controlled trial. Lancet. 2002;360:217–22.

15. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane 

PW, Mckillop JH, Packard CJ. Prevention of coronary heart disease 

with pravastatin in men with hypercholesterolaemia. West of Scotland 

Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307. 

DOI: 10.1056/NEJM19951116333001.

16. Study of the Effectiveness of Additional Reductions in C, Homocysteine 

Collaborative G, Armitage J, Bowman L, Wallendszus K, Bulbulla R, 

Rahimi K, Haynes R, Parish S, Peto R, Collins R. Intensive lowering of 

LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 

survivors of myocardial infarction: a double-blind randomised trial. 

Lancet. 2010;376:1658–1669.

17. Sardella G, Lucisano L, Mancone M, Conti G, Calacino S, Stio RE, 

Pennacchi M, Biondi-Zoccai G, Canali E, Fedele F. Comparison of 

High Releasing Rosuvastatin and Atorvastatin Pretreatment in Patients 

Undergoing Elective PCI to Reduce the Incidence of Myocardial 

Periprocudural Necrosis. The ROMA II trial. Int J Cardiol. 2013;168:3715– 

3720.DOI: 10.1016/j.ijcard.2013.06.017.

18. Zhao SP, Yu BL, Peng DQ, HU Y. The effect of moderate-dose versus 

sus double-dose statins on patients with acute coronary syndrome in 

China: results of the CHILLAS trial. Atherosclerosis. 2014;233:707–712. 

DOI: 10.1016/j.atherosclerosis.2013.12.003.

19. Liu PY, Lin LY, Lin HJ, Hsia CH, Hung YR, Yeh HL, Wu TC, Chen JY, 

Chen KL, Chen JW. Pravastatin and Atorvastatin Double-Blind Randomized 

Comparative Study Among High-Risk Patients, Including Those With 

Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study). PLoS One. 

2013;8:e62986.DOI: 10.1371/journal.pone.0062986.

20. Nicholas SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby 

P, Raichlen JS, Uno K, Borgman M, Wolski K, et al. Effect of two inten-

sive statin regimens on progression of coronary disease. N Engl J Med. 

2011;365:2078–2087.DOI: 10.1056/NEJMoa110874.

21. Liu Z, Hao H, Yin C, Chu Y, Li J, Xu D. Therapeutic effects of atorvastatin 

and ezetimibe compared with double-dose atorvastatin in very elderly 

patients with acute coronary syndrome. Oncotarget. 2017;8:41582– 

41589.DOI: 10.18632/oncotarget.15078.
22. Farnier M, Averna M, Missault L, Vaverkova H, Viggia M, Massaad R, Vandormael K, Johnson-Leonvos AQ, Bruci P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosvastatin 10 mg in high-risk hypercholesterolemic patients inadequately controlled with prior statin monotherapy—the IN-CROSS study. Int J Clin Pract. 2009;63:547–559.

23. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, Hong MK, Kim BK, Oh SJ, Jeon DW, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMt trial. JACC Cardiovasc Interv. 2010;3:332–339. DOI: 10.1016/j.jcin.2009.11.021.

24. Berwanger O, Santucci EV, de Barros e Silva PG, Jesuíno ID, Damiani LP, Barbosa LM, Santos RH, Laranjeira LN, Egydio FD, Borges de Oliveira JA, et al. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial. JAMA. 2018;319:1331–1340. DOI: 10.1001/jama.2018.2444.

25. Yoshimura S, Uchida K, Takashima R, Kimura K, Morimoto T, Tanada S, Iida T, Kuroda J, Nose A, et al. Randomized controlled trial of early versus delayed statin therapy in patients with acute ischemic stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke. 2017;48:3057–3063. DOI: 10.1161/STROKEAHA.117.017623.

26. Alkhalil M. Mechanistic insights to target atherosclerosis residual risk. Curr Probl Cardiol. 2019;40:62. [Epub ahead of print]. DOI: 10.1016/j.cprocar.2019.06.004.

27. Alkhalil M. Atorvastatin in polyvascular atherosclerotic disease. J Am Coll Cardiol. 2020;75:240–241. DOI: 10.1016/j.jacc.2019.09.072.

28. Collins R, Reith C, Emerson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, et al. Randomized of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561. DOI: 10.1016/S0140-6736(16)31357-5.

29. Alkhalil M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Alkhalil et al Intensive Lipid-Lowering in Polyvascular Disease

30. Hibi K, Kimura T, Kimura K, Morimoto T, Hiro T, Miyauchi K, Nakagawa J. J Am Heart Assoc. 2021;10:e017948. DOI: 10.1161/JAHA.120.017948.

31. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373–2384. DOI: 10.1001/jama.2016.16951.

32. Alkhalil M, Biasioli L, Akbar N, Galassi F, Chai JT, Robson MD, Choudhury RP. T2 mapping MRI technique quantifies carotid plaque lipid, and its depletion after statin initiation, following acute myocardial infarction. Atherosclerosis. 2018;279:100–106. DOI: 10.1016/j.atherosclerosis.2018.08.033.

33. Kini AS, Baber Ü, Kovacic JC, Limaye A, Ali ZA, Sweeny J, Maehara A, Mehran R, Dangas G, Mintz GS, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62:21–29.

34. Alkhalil M, Biasioli L, Chai JT, Galassi F, Li L, Darby C, Halliday A, Hands L, Magee T, Perkins J, et al. Quantification of carotid plaque lipid content with magnetic resonance T2 mapping in patients undergoing carotid endarterectomy. PLoS One. 2017;12:e0181668. DOI: 10.1371/journal.pone.0181668.

35. Sun J, Zhao XQ, Balu N, Neraldele MB, Irquith DA, Yamada K, Cantón G, Crouse JR III, Anderson TJ, Huston J III, et al. Carotid plaque lipid content and fibrous cap status predict systemic CV outcomes: the MRI substudy in AIM-HIGH. JACC Cardiovasc Imaging. 2017;10:241–249. DOI: 10.1016/j.jcmg.2016.06.017.

36. Zavodni AE, Wasserman BA, McClelland RL, Gomes AS, Folsom AR, Polak JF, Lima JA, Bluemke DA. Carotid artery plaque morphology and composition in relation to incident cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA). Radiology. 2014;271:381–389. DOI: 10.1148/radiol.14131020.

37. Alkhalil M, Chai JT, Choudhury RP. Plaque imaging to refine indications for emerging lipid-lowering drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:58–67. DOI: 10.1093/ehjcvp/pwv034.

38. Waksman R, Di Mario C, Torguson R, Ali ZA, Singh V, Skinner WH, Szarek D, Bell MR, Diekmann J, Gorelik B, et al. Evaluation of plaque composition by intravascular ultrasound and three-dimensional intravascular optical coherence tomography: a prospective cohort study. Lancet. 2019;394:1629–1637. DOI: 10.1016/S0140-6736(19)31794-5.

39. O’Donoghue ML, Fazio S, Giugliano RP, Stroes ES, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Česka R, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–1492. DOI: 10.1161/CIRCULATIONAHA.118.037184.